Grigoriadis Dimitri E. 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Oct 12, 2021
Insider Transaction Report
Form 4
Grigoriadis Dimitri E.
Vice President, Research
Transactions
- Sale
Common Stock
2021-10-07$104.85/sh−5,000$524,260→ 82,273 total - Exercise/Conversion
Common Stock
2021-10-07$43.24/sh+5,000$216,200→ 87,273 total - Sale
Common Stock
2021-10-07$104.75/sh−3,000$314,250→ 82,273 total - Exercise/Conversion
Non-Qualified Stock Option
2021-10-07$43.24/sh−5,000$216,200→ 43,400 totalExercise: $43.24Exp: 2027-02-06→ Common Stock (5,000 underlying)
Footnotes (4)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.75 to $104.755. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.75 to $105.085. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]Option granted February 06, 2017 and vested monthly over four years.